Efficacies of HDDT With or Without Bismuth vs Amoxicillin-metronidazole BQT for First-line H Pylori Eradication

PHASE4CompletedINTERVENTIONAL
Enrollment

603

Participants

Timeline

Start Date

May 30, 2019

Primary Completion Date

February 11, 2025

Study Completion Date

February 17, 2025

Conditions
Helicobacter Pylori Infection
Interventions
DRUG

High-dose dual therapy (rabeprazole, amoxicillin)

High-dose dual therapy (rabeprazole 20 mg qid + amoxicillin 750 mg qid, for 14 days)

DRUG

Bismuth High-dose dual therapy (rabeprazole, amoxicillin, tripotassium dicitrate bismuthate)

Bismuth-High-dose dual therapy (rabeprazole 20 mg qid + amoxicillin 750 mg qid + tripotassium dicitrate bismuthate 300 mg qid, for 14 days)

DRUG

Amoxicillin-Metronidazole Bismuth quadruple therapy

Amoxicillin-Metronidazole Bismuth quadruple therapy (rabeprazole 20 mg bid + tripotassium dicitrate bismuthate 600 mg bid + amoxicillin 1000 mg bid + metronidazole 500 mg tid, for 14 days)

Trial Locations (1)

10002

National Taiwan University Hospital, Taipei

All Listed Sponsors
collaborator

Ministry of Science and Technology, Taiwan

OTHER_GOV

lead

National Taiwan University Hospital

OTHER

NCT03897244 - Efficacies of HDDT With or Without Bismuth vs Amoxicillin-metronidazole BQT for First-line H Pylori Eradication | Biotech Hunter | Biotech Hunter